2019.07.10 Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment
2019.07.03 University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease
2019.06.28 BNO BIO, a joint company by Bukwang and OCI, invests in a bio-venture that develop a technology in early detection of cancer
2019.06.26 Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries
2018.01.31 Bukwang Pharmaceutical Co., Ltd. registered patents on a therapeutic candidate for dyskinesia in Parkinson's Disease patients.
2018.01.26 Bukwang Pharmaceutical Co., Ltd. a novel candidate for type 2 diabetes, MLR-1023 is undergoing global phase 2b study.
- Approximately 50% patients are enrolled since the first patient dosed.
2017.09.11 Bukwang’s novel type 2 diabetes drug candidate “MLR-1023” initiated patients screening in global Phase 2b.
2017.04.07 Bukwang announces the conclusion of an exclusive license agreement with Sumitomo Dainippon Pharma on lurasidone HCI for Korea
2017.01.05 Bukwang Pharmaceutical Co., Ltd. ‘JM-010’, a treatment of dyskinesia in Parkinson's Disease patients, is approved for Orphan Drug Designation
2017.01.04 Bukwang launched cosmetic products to target Dermocosmetic industry Importing ‘Repavar’ products from Spain Ferrer and expecting to expand
2016.12.19 Bukwang Pharmaceutical Co., Ltd, submitted Phase 2b IND for new diabetic drug candidate, MLR-1023
2016.08.09 First patient dosed in pharmacokinetic clinical trial of JM-010, a new drug candidate for the treatment of dyskinesia in Parkinson's Disease patents
under development at Bukwang
2016.05.02 Received IND approval from MFDS on phase 1 clinical study of BKP-1502, Bukwang’s incrementally modified drug of Viread (tenofovir)
2016.05.12 Installed a nuclear magnetic resonance spectrometer at the R&D Center
2016.06.13 Poster presentation of phase 2a results of MLR-1023, a new drug candidate for type 2 diabetes, at the American Diabetes Association
2016.06.30 Signed distribution agreement with Ferrer on Repavar (cosmetic for atopic dermatitis) and Melagyn (feminine cleanser)
2016.07.01 Completed transfer of regulatory approval on Selbex Cap. to Bukwang, signed license and supply agreement with Eisai,
and signed sales and purchase agreement with Eisai Korea
2016.07.05 JM-010 phase 1 study Study Initiation Visit